Vetoryl (Trilostane) 5 mg Capsules- 30ct bottle

DESCRIPTION:

Vetoryl (Trilostane) Capsules are available in 5 sizes (5, 10, 30, 60 mg and 120 mg) for oral administration based on body weight. Trilostane (4α,5α-epoxy-17β-hydroxy-3-oxoandrostane-2α-carbonitrile) is an orally active synthetic steroid analogue that selectively inhibits 3 β-hydroxysteroid dehydrogenase in the adrenal cortex, thereby inhibiting the conversion of pregnenolone to progesterone.

USES:

Vetoryl (Trilostane) Capsules are indicated for the treatment of pituitary-dependent hyperadrenocorticism and the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. See package insert for complete product details.

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not give this medication to pregnant dogs, or dogs with kidney or liver disease. Consult with your veterinarian if your dog is taking other medications.

Possible Side Effects:

In rare cases poor/reduced appetite, vomiting, lethargy/dullness, diarrhea, and weakness. Occasionally, more serious reactions, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis or adrenal necrosis/rupture may occur.

WARNINGS:

Keep out of reach of children. Not for human use. Trilostane may decrease testosterone and progesterone synthesis. Women who are pregnant or are intending to become pregnant should avoid handling the capsules. The content of the capsules may cause skin and eye irritation and sensitisation. Do not divide or open capsules. In the event of accidental breakage of the capsules and contact of the granules with eye or skin, wash immediately with plenty of water. If irritation persists, seek medical advice. In the event of accidental ingestion, seek medical advice immediately and take the labelled container with you.

PRECAUTIONS:

The most common adverse reactions reported are poor/reduced appetite, vomiting, lethargy/dullness, diarrhea and weakness. Occasionally, more serious reactions, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis or adrenal necrosis/rupture may occur, and may result in death. 107 dogs were treated in Phase 1 of a 13 centre, open label, 84 day study in the US. Dogs ranged from 6-16 years and weighed 3-54 kg. 91 dogs continued into Phase 2 for a further 91-529 days (mean 348 days). During Phase 1 (up to day 84 of Vetoryl treatment), adverse events were observed in 93 dogs (87%); during Phase 2 adverse events were observed in 88 dogs (96%). In both phases of the US field study, the following adverse reactions (most of which were mild and transient) were seen:

INFORMATION FOR DOG OWNERS:

Be aware that the following side effects may indicate that your dog is having a problem with Vetoryl capsules: â—� Stops eating or loses interest in food. â—� Vomiting. â—� Change in bowel movement (such as diarrhea or loose stools). â—� Depression, lethargy or decreased activity. As Vetoryl capsules control the hyperadrenocoticism, there should be a decrease in food and water consumption to normal levels.

STORAGE:

Store between 15°C and 30°C.